HK1180541A1 - Stabilized statin formulations - Google Patents
Stabilized statin formulationsInfo
- Publication number
- HK1180541A1 HK1180541A1 HK13107910.7A HK13107910A HK1180541A1 HK 1180541 A1 HK1180541 A1 HK 1180541A1 HK 13107910 A HK13107910 A HK 13107910A HK 1180541 A1 HK1180541 A1 HK 1180541A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- statin formulations
- stabilized statin
- stabilized
- formulations
- statin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/762,025 US8372877B2 (en) | 2010-04-16 | 2010-04-16 | Stabilized statin formulations |
| PCT/US2011/031388 WO2011130079A1 (en) | 2010-04-16 | 2011-04-06 | Stabilized statin formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1180541A1 true HK1180541A1 (en) | 2013-10-25 |
Family
ID=44788660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13107910.7A HK1180541A1 (en) | 2010-04-16 | 2013-07-06 | Stabilized statin formulations |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US8372877B2 (ja) |
| EP (2) | EP2557919B1 (ja) |
| JP (2) | JP5938394B2 (ja) |
| KR (1) | KR101462326B1 (ja) |
| CN (1) | CN102892287B (ja) |
| AU (1) | AU2011240925B2 (ja) |
| BR (1) | BR112012026465A2 (ja) |
| CA (1) | CA2799550C (ja) |
| ES (1) | ES2720954T3 (ja) |
| HK (1) | HK1180541A1 (ja) |
| WO (1) | WO2011130079A1 (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8372877B2 (en) * | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
| CA2852904C (en) | 2010-10-19 | 2019-01-08 | University Of Miami | Assays, methods and kits for predicting renal disease and personalized treatment strategies |
| US9592296B2 (en) * | 2011-09-08 | 2017-03-14 | Hexal Ag | Pharmaceutical composition for oral administration with a statin |
| CN104244956B (zh) * | 2012-04-13 | 2020-04-17 | L&F研究有限公司 | 使用环糊精的方法 |
| WO2014079151A1 (zh) * | 2012-11-23 | 2014-05-30 | 北京大学第三医院 | 他汀类化合物在制备治疗肥胖症、糖尿病、高血压、高血脂的局部用药物中的用途 |
| US9974767B2 (en) | 2014-07-14 | 2018-05-22 | University Of Washington | Statins in the treatment of muscular dystrophies and myopathies |
| KR101686881B1 (ko) * | 2014-07-25 | 2016-12-20 | 연세대학교 산학협력단 | 스타틴을 포함하는 갑상선 안병증의 예방 또는 치료용 약제학적 조성물 |
| JP6355688B2 (ja) * | 2016-09-01 | 2018-07-11 | ペキン ユニバーシティ サード ホスピタルＰｅｋｉｎｇ Ｕｎｉｖｅｒｓｉｔｙ Ｔｈｉｒｄ Ｈｏｓｐｉｔａｌ | 虚血性疾患の治療におけるスタチンの使用 |
| KR102099627B1 (ko) | 2018-04-13 | 2020-04-10 | (주)바이오리치 | 냉이 추출물 및 신이 추출물을 유효성분으로 포함하는 지질 대사 개선용 조성물 |
| CN110237055B (zh) * | 2019-07-15 | 2021-09-07 | 江苏中兴药业有限公司 | 一种水飞蓟宾与辛伐他汀的药物组合物及其制备方法与应用 |
| GB2624171A (en) | 2022-11-08 | 2024-05-15 | Novumgen Ltd | An orally disintegrating tablet containing atorvastatin and process of preparing the same |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4246227A (en) | 1979-02-26 | 1981-01-20 | Trayco, Inc. | Method of making a unitary bowl, waterway, and trap for a toilet |
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| HU204253B (en) | 1982-11-22 | 1991-12-30 | Sandoz Ag | Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them |
| US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4739073A (en) | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| US4588715A (en) | 1984-06-04 | 1986-05-13 | Sandoz, Inc. | Heptenoic acid derivatives |
| US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
| US4804679A (en) | 1984-07-24 | 1989-02-14 | Sandoz Pharm. Corp. | Erythro-(E)-7-(3'-C1-3alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl)-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
| US5001255A (en) | 1984-12-04 | 1991-03-19 | Sandoz Pharm. Corp. | Idene analogs of mevalonolactone and derivatives thereof |
| US4808607A (en) | 1985-05-22 | 1989-02-28 | Sandoz Pharm. Corp. | Imidazole analogs of mevalonolactone and derivatives thereof for use in inhibiting cholesterol biosynthesis and lowering blood cholesterol level |
| US4755606A (en) | 1985-05-22 | 1988-07-05 | Sandoz Pharm. Corp. | Imidazolyl-3,5-di-(diphenyl-butylsilyloxy) carboxylic acid ester intermediates |
| US4851427A (en) | 1985-10-25 | 1989-07-25 | Sandoz Pharm. Corp. | Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use |
| US4829081A (en) | 1986-01-07 | 1989-05-09 | Sandoz Pharm. Corp. | Analogs of mevalonolactone and derivatives thereof |
| US4927851A (en) | 1986-01-07 | 1990-05-22 | Sandoz Pharm. Corp. | Analogs of mevalonolactone and derivatives thereof |
| US4751235A (en) | 1986-12-23 | 1988-06-14 | Sandoz Pharm. Corp. | Anti-atherosclerotic indolizine derivatives |
| US4939159A (en) | 1986-09-10 | 1990-07-03 | Sandoz Pharm. Corp. | Azaindole derivatives useful as cholesterol biosynthesis inhibitors |
| DE3817808A1 (de) | 1987-07-21 | 1989-02-02 | Bayer Ag | Verfahren zur herstellung von 2-substituierten pyrrolen |
| CA1336714C (en) | 1987-08-20 | 1995-08-15 | Yoshihiro Fujikawa | Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis |
| EP0308736A3 (en) | 1987-09-12 | 1990-02-14 | Nissan Chemical Industries Ltd. | Pyrimidine type mevalonolactones |
| US4868185A (en) | 1987-12-10 | 1989-09-19 | Warner-Lambert Company | 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis |
| DE3800785A1 (de) | 1988-01-09 | 1989-07-20 | Hoechst Ag | Substituierte 7-(pyridazin-5-yl)-3,5-dihydroxyheptan(en)- saeuren, ihre entsprechenden (delta)-lactone bzw. derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte |
| US4822799A (en) | 1988-01-27 | 1989-04-18 | Sandoz Pharm. Corp. | Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals |
| NO890521L (no) | 1988-02-25 | 1989-08-28 | Bayer Ag | Substituerte pyrimidiner. |
| US4876280A (en) | 1988-03-10 | 1989-10-24 | Sandoz Pharm. Corp. | Arylcyclohexane and arylcyclohexene analogs of mevalonolactone derivatives and their use |
| FI894648A (fi) | 1988-10-03 | 1990-04-04 | Glaxo Group Ltd | Kemiska foereningar. |
| KR900701778A (ko) | 1988-10-06 | 1990-12-04 | 예안 크라머, 한스 루돌프 하우스 | 피리미디닐- 치환된 하이드록시산, 락톤 및 에스테르, 및 이를 함유하는 약학적 조성물 |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5177080A (en) | 1990-12-14 | 1993-01-05 | Bayer Aktiengesellschaft | Substituted pyridyl-dihydroxy-heptenoic acid and its salts |
| JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| HU217629B (hu) | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
| PL186907B1 (pl) | 1995-12-22 | 2004-03-31 | Kowa Co | Kompozycja farmaceutyczna stabilizowana czynnikiem zasadowym |
| US6699849B1 (en) * | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| EP1092552B1 (en) | 1999-03-05 | 2004-09-29 | Nippon Paper Industries Co., Ltd. | Thermal recording material |
| EP1425311A4 (en) | 2001-01-11 | 2004-12-01 | Eastman Chem Co | CYCLODEXTRINSULFONATES, GUEST INCLUDING COMPLEXES, METHOD FOR THEIR PRODUCTION AND RELATED MATERIALS |
| US6566347B1 (en) | 2001-08-22 | 2003-05-20 | Duquesne University Of The Holy Ghost | Controlled release pharmaceutical |
| OA12777A (en) * | 2002-02-14 | 2006-07-06 | Ranbaxy Lab Ltd | Formulations of atorvastatin stabilized with alkali metal additions. |
| CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
| US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US7842716B2 (en) * | 2004-03-29 | 2010-11-30 | HeartDrug Research, LLC | Treating vascular events with statins by inhibiting PAR-1 and PAR-4 |
| MX2007004722A (es) * | 2004-10-28 | 2007-06-15 | Warner Lambert Co | Procedimiento para formar atorvastatina amorfa. |
| ES2277743B2 (es) * | 2005-06-02 | 2008-12-16 | Universidade De Santiago De Compostela | Nanoparticulas que comprenden quitosano y ciclodextrina. |
| US20090247603A1 (en) * | 2005-12-23 | 2009-10-01 | Orbus Pharma, Inc. | Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor |
| WO2008032327A2 (en) * | 2006-09-14 | 2008-03-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Organic nanoparticles obtained from microemulsions by solvent evaporation |
| ES2310122B1 (es) | 2007-04-20 | 2009-10-30 | Instituto Cientifico Y Tecnologico De Navarra, S.A | Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones. |
| CN101658677A (zh) * | 2009-09-09 | 2010-03-03 | 重庆大学 | 洛伐他汀-磺丁基醚-β-环糊精包合物、制剂及制备方法 |
| US8372877B2 (en) | 2010-04-16 | 2013-02-12 | Cumberland Pharmaceuticals | Stabilized statin formulations |
-
2010
- 2010-04-16 US US12/762,025 patent/US8372877B2/en active Active
-
2011
- 2011-04-06 CN CN201180022077.3A patent/CN102892287B/zh active Active
- 2011-04-06 EP EP11769321.8A patent/EP2557919B1/en active Active
- 2011-04-06 BR BR112012026465A patent/BR112012026465A2/pt active Search and Examination
- 2011-04-06 EP EP18215075.5A patent/EP3524053A1/en not_active Withdrawn
- 2011-04-06 ES ES11769321T patent/ES2720954T3/es active Active
- 2011-04-06 AU AU2011240925A patent/AU2011240925B2/en not_active Ceased
- 2011-04-06 JP JP2013504949A patent/JP5938394B2/ja not_active Expired - Fee Related
- 2011-04-06 KR KR1020127029757A patent/KR101462326B1/ko active IP Right Grant
- 2011-04-06 WO PCT/US2011/031388 patent/WO2011130079A1/en active Application Filing
- 2011-04-06 CA CA2799550A patent/CA2799550C/en active Active
-
2013
- 2013-01-22 US US13/746,999 patent/US8933115B2/en active Active
- 2013-07-06 HK HK13107910.7A patent/HK1180541A1/xx not_active IP Right Cessation
-
2014
- 2014-11-11 US US14/538,464 patent/US9820966B2/en active Active
-
2016
- 2016-02-19 JP JP2016030191A patent/JP6178444B2/ja not_active Expired - Fee Related
-
2017
- 2017-10-20 US US15/789,506 patent/US20180036282A1/en not_active Abandoned
-
2018
- 2018-08-13 US US16/102,381 patent/US20180344693A1/en not_active Abandoned
- 2018-12-21 US US16/231,132 patent/US20190117621A1/en not_active Abandoned
-
2020
- 2020-06-29 US US16/849,693 patent/US20200316022A1/en not_active Abandoned
- 2020-10-23 US US17/078,180 patent/US20210106561A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR101462326B1 (ko) | 2014-11-14 |
| JP6178444B2 (ja) | 2017-08-09 |
| AU2011240925B2 (en) | 2015-01-15 |
| US20150065553A1 (en) | 2015-03-05 |
| US20160128977A9 (en) | 2016-05-12 |
| US20110257240A1 (en) | 2011-10-20 |
| EP2557919B1 (en) | 2019-01-30 |
| US20200316022A1 (en) | 2020-10-08 |
| EP3524053A1 (en) | 2019-08-14 |
| US8372877B2 (en) | 2013-02-12 |
| US20190117621A1 (en) | 2019-04-25 |
| KR20130020788A (ko) | 2013-02-28 |
| CA2799550C (en) | 2015-03-17 |
| JP5938394B2 (ja) | 2016-06-22 |
| BR112012026465A2 (pt) | 2017-07-11 |
| CN102892287A (zh) | 2013-01-23 |
| US20130137745A1 (en) | 2013-05-30 |
| CA2799550A1 (en) | 2011-10-20 |
| US20180036282A1 (en) | 2018-02-08 |
| JP2016166179A (ja) | 2016-09-15 |
| EP2557919A1 (en) | 2013-02-20 |
| CN102892287B (zh) | 2014-11-05 |
| US20180344693A1 (en) | 2018-12-06 |
| EP2557919A4 (en) | 2013-12-25 |
| WO2011130079A1 (en) | 2011-10-20 |
| US9820966B2 (en) | 2017-11-21 |
| ES2720954T3 (es) | 2019-07-25 |
| AU2011240925A1 (en) | 2012-11-15 |
| JP2013525301A (ja) | 2013-06-20 |
| US8933115B2 (en) | 2015-01-13 |
| US20210106561A1 (en) | 2021-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1180541A1 (en) | Stabilized statin formulations | |
| GB201008005D0 (en) | Pharmaceutical compounds | |
| ZA201208110B (en) | Stabilized agrochemical composition | |
| EP2588141A4 (en) | ANTIBODY FORMULATIONS | |
| GB201020161D0 (en) | Pharmaceutical compounds | |
| ZA201207375B (en) | Stabilized pharmaceutical composition | |
| EP2400840A4 (en) | LIQUID STATINE FORMULATIONS | |
| ZA201300194B (en) | Formulations | |
| SI2407155T1 (sl) | Preparati na osnovi inekalcitola | |
| GB201110193D0 (en) | Formulations | |
| GB201013513D0 (en) | Formulations | |
| ZA201300196B (en) | Formulations | |
| GB201018647D0 (en) | Formulations | |
| GB201018645D0 (en) | Formulations | |
| GB201018648D0 (en) | Formulations | |
| GB201018649D0 (en) | Formulations | |
| GB201012589D0 (en) | Formulations | |
| GB201010494D0 (en) | Formulations | |
| GB201008470D0 (en) | Formulations | |
| GB201008358D0 (en) | Formulations | |
| GB201007959D0 (en) | Formulations | |
| GB201007702D0 (en) | Formulations | |
| GB201005587D0 (en) | Novel formulations | |
| AP3434A (en) | Semisolid pharmaceutical formulations | |
| GB201012047D0 (en) | Pharmaceutical formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230411 |